US 12,655,195 B2 · HLA class II-restricted DQ T cell receptors against RAS with G13D mutation

Abstract

Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 13 with aspartic acid. The TCRs may recognize G13D RAS presented by an HLA-DQ heterodimer. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

Claims21

Dependent claims

An isolated or purified T-cell receptor (TCR) having antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 13 with aspartic acid,

wherein the mutated human RAS amino acid sequence is a mutated human Kirsten rat sarcoma viral oncogene homolog (KRAS), a mutated human Harvey rat sarcoma viral oncogene homolog (HRAS), or a mutated human Neuroblastoma rat sarcoma viral oncogene homolog (NRAS) amino acid sequence,
wherein position 13 is defined by reference to the wild-type human KRAS, wild-type human HRAS, or wild-type human NRAS protein, respectively, and
wherein the TCR comprises:
(a) all of SEQ ID NOs:
1-6,
(b) all of SEQ ID NOs:
11-16,
(c) all of SEQ ID NOs:
21-26,
(d) all of SEQ ID NOs:
31-36,
(e) all of SEQ ID NOs:
41-46,
(f) all of SEQ ID NOs:
119-124,
(g) all of SEQ ID NOs:
129-134,
(h) all of SEQ ID NOs:
139-144,
(i) all of SEQ ID NOs:
149-154,
(j) all of SEQ ID NOs:
159-164,
(k) all of SEQ ID NOs:
169-174, or
(l) all of SEQ ID NOs:
179-184.

24 more elements

An isolated or purified protein, comprising:

(a) a first polypeptide chain comprising the amino acid sequences of SEQ ID NOs:
1-3 and a second polypeptide chain comprising the amino acid sequences of SEQ ID NOs:
4-6;
(b) a first polypeptide chain comprising the amino acid sequences of SEQ ID NOs:
11-13 and a second polypeptide chain comprising the amino acid sequences of SEQ ID NOs:
14-16;
(c) a first polypeptide chain comprising the amino acid sequences of SEQ ID NOs:
21-23 and a second polypeptide chain comprising the amino acid sequences of SEQ ID NOs:
24-26;
(d) a first polypeptide chain comprising the amino acid sequences of SEQ ID NOs:
31-33 and a second polypeptide chain comprising the amino acid sequences of SEQ ID NOs:
34-36;
(e) a first polypeptide chain comprising the amino acid sequences of SEQ ID NOs:
41-43 and a second polypeptide chain comprising the amino acid sequences of SEQ ID NOs:
44-46;
(f) a first polypeptide chain comprising the amino acid sequences of all of SEQ ID NOs:
119-121 and a second polypeptide chain comprising the amino acid sequences of all of SEQ ID NOs:
122-124;
(g) a first polypeptide chain comprising the amino acid sequences of all of SEQ ID NOs:
129-131 and a second polypeptide chain comprising the amino acid sequences of all of SEQ ID NOs:
132-134;
(h) a first polypeptide chain comprising the amino acid sequences of all of SEQ ID NOs:
139-141 and a second polypeptide chain comprising the amino acid sequences of all of SEQ ID NOs:
142-144;
(i) a first polypeptide chain comprising the amino acid sequences of all of SEQ ID NOs:
149-151 and a second polypeptide chain comprising the amino acid sequences of all of SEQ ID NOs:
152-154;
(j) a first polypeptide chain comprising the amino acid sequences of all of SEQ ID NOs:
159-161 and a second polypeptide chain comprising the amino acid sequences of all of SEQ ID NOs:
162-164;
(k) a first polypeptide chain comprising the amino acid sequences of all of SEQ ID NOs:
169-171 and a second polypeptide chain comprising the amino acid sequences of all of SEQ ID NOs:
172-174;
or
(l) a first polypeptide chain comprising the amino acid sequences of all of SEQ ID NOs:
179-181 and a second polypeptide chain comprising the amino acid sequences of all of SEQ ID NOs:
182-184.

34 more elements

An isolated or purified nucleic acid comprising, from 5′ to 3′, a first nucleotide sequence and a second nucleotide sequence, wherein the first and second nucleotide sequence, respectively, encode the amino sequences of SEQ ID NOs:

7 and 8;
8 and 7;
9 and 10;
10 and 9;
17 and 18;
18 and 17;
19 and 20;
20 and 19;
27 and 28;
28 and 27;
29 and 30;
30 and 29;
37 and 38;
38 and 37;
39 and 40;
40 and 39;
47 and 48;
48 and 47;
49 and 50;
50 and 49;
125 and 126;
126 and 125;
127 and 128;
128 and 127;
135 and 136;
136 and 135;
137 and 138;
138 and 137;
145 and 146;
146 and 145;
147 and 148;
148 and 147;
155 and 156;
156 and 155;
157 and 158;
158 and 157;
165 and 166;
166 and 165;
167 and 168;
168 and 167;
175 and 176;
176 and 175;
177 and 178;
178 and 177;
185 and 186;
186 and 185;
187 and 188;
188 and 187;
65 and 66;
66 and 65;
67 and 68;
68 and 67;
69 and 70;
70 and 69;
71 and 72;
72 and 71;
73 and 74;
74 and 73;
75 and 76;
76 and 75;
77 and 78;
78 and 77;
79 and 80;
80 and 79;
81 and 82;
82 and 81;
83 and 84;
84 and 83;
85 and 86;
86 and 85;
87 and 88;
88 and 87;
89 and 90;
90 and 89;
91 and 92;
92 and 91;
93 and 94;
94 and 93;
95 and 96;
96 and 95;
97 and 98;
98 and 97;
99 and 100;
100 and 99;
101 and 102;
102 and 101;
103 and 104;
104 and 103;
189 and 190;
190 and 189;
191 and 192;
192 and 191;
193 and 194;
194 and 193;
195 and 196;
196 and 195;
197 and 198;
198 and 197;
199 and 200;
200 and 199;
201 and 202;
202 and 201;
203 and 204;
204 and 203;
205 and 206;
206 and 205;
207 and 208;
208 and 207;
209 and 210;
210 and 209;
211 and 212;
212 and 211;
213 and 214;
214 and 213;
215 and 216;
216 and 215;
217 and 218;
218 and 217;
219 and 220;
220 and 219;
221 and 222;
222 and 221;
223 and 224;
224 and 223;
225 and 226;
226 and 225;
227 and 228;
228 and 227;
229 and 230;
230 and 229;
231 and 232;
232 and 231;
233 and 234;
234 and 233;
235 and 236;
236 and 235;
237 and 238;
238 and 237;
239 and 240;
240 and 239;
241 and 242;
242 and 241;
243 and 244;
or 244 and 243.

141 more elements

Dependencies are inferred from the claim text.

Facts

Application

18/027,981Filed 1 Oct 2021 · us provisional application

Priority

2 Oct 2020

Published

US 2023/0365649 A116 Nov 2023

Granted

16 Jun 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification12 codes

C07K 14/7051
Immunoglobulin superfamily: t-cell receptor -CD3 complex
A61K 35/17
Blood; Artificial blood: lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/32
Characterised by the recombinant expression of specific molecules in the cells of the immune system: t-cell receptors [TCR]

Abstract

Facts

Application

18/027,981Filed 1 Oct 2021 · us provisional application

Priority

2 Oct 2020

Published

US 2023/0365649 A116 Nov 2023

Granted

16 Jun 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification12 codes

C07K 14/7051
Immunoglobulin superfamily: t-cell receptor -CD3 complex
A61K 35/17
Blood; Artificial blood: lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/32
Characterised by the recombinant expression of specific molecules in the cells of the immune system: t-cell receptors [TCR]

HLA class II-restricted DQ T cell receptors against RAS with G13D mutation

Life of this patent

Abstract

Claims21

HLA class II-restricted DQ T cell receptors against RAS with G13D mutation

Life of this patent

Abstract

Claims21